Companies covered: Medtronic, Inc. (NYSE:MDT), Stryker Corporation (NYSE:SYK), Intuitive Surgical, Inc. (NASDAQ:ISRG), GE HealthCare Technologies Inc. (NASDAQ:GEHC), Johnson & Johnson (NYSE:JNJ), Globus Medical, Inc. (NYSE:GMED), NuVasive, Inc. (NASDAQ:NUVA), Orthofix International N.V. (NASDAQ:OFIX), Abbott Laboratories (NYSE:ABT), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Penumbra Inc. (NYSE:PEN), Treace Medical Concepts Inc. (NASDAQ:TMCI), Avita Medical Inc. (NASDAQ:RCEL), LENSAR Inc. (NASDAQ:LNSR), Humacyte Inc. (NASDAQ: HUMA), DexCom, Inc. (NASDAQ:DXCM), Boston Scientific Corporation (NYSE:BSX), RxSight Inc. (NASDAQ:RXST), Integra LifeSciences Holdings Corporation (NASDAQ:IART), P3 Healthcare Partners Inc. (NASDAQ:PIII), Apollo Medical Holdings, Inc. (NASDAQ:AMEH), Viemed Healthcare Inc. (NASDAQ:VMD), InfuSystems Holdings, Inc. (NYSEAMERICAN:INFU), iCAD, Inc. (NASDAQ:ICAD), Augmedix Inc. (NASDAQ:AUGX), Alphatec Holdings, Inc. (NASDAQ:ATEC), Harrow Health Inc. (NASDAQ:HROW), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Modivcare Inc. (NASDAQ:MODV), Smith & Nephew SNATS, Inc. (NYSE:SNN), IDEXX Laboratories, Inc. (NASDAQ:IDXX), Hologic, Inc. (NASDAQ:HOLX), Siemens AG (OTCMKTS:SIEGY), Zoetis Inc. (NYSE:ZTS), Illumina, Inc. (NASDAQ:ILMN), Clearpoint Neuro Inc. (NASDAQ:CLPT), Xtant Medical Holdings Inc. (NYSEAMERICAN:XTNT), Materialise NV (NASDAQ:MTLS)
Companies covered: IVERIC bio Inc. (NASDAQ:ISEE), Disc Medicine Inc. (NASDAQ:IRON), Nuvalent Inc. (NASDAQ:NUVL), Apellis Pharmaceuticals Inc. (NASDAQ:APLS), Amgen Inc. (NASDAQ:AMGN), Horizon Therapeutics PLC (NASDAQ:HZNP), Ipsen ADR (OTCMKTS:IPSEY), Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA), BioNTech SE (ADR) (NASDAQ:BNTX), Theseus Pharmaceuticals Inc. (NASDAQ:THRX), Mersana Therapeutics Inc. (NASDAQ:MRSN), Argenx SE (ADR) (NASDAQ:ARGX), Genmab A/S - ADR (NASDAQ:GMAB), Janux Therapeutics Inc. (NASDAQ:JANX)), Johnson & Johnson (NYSE:JNJ), AbbVie Inc. (NYSE:ABBV), Seagen Inc. (NASDAQ:SGEN), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Chinook Therapeutics Inc. (NASDAQ:KDNY), Pfizer, Inc. (NYSE:PFE), Lisata Therapeutics Inc. (NASDAQ:LSTA), Omeros Corporation (NASDAQ:OMER), Cidara Therapeutics Inc. (NASDAQ:CDTX), Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), United Therapeutics Corporation (NASDAQ:UTHR), Astria Therapeutics Inc. (NASDAQ:ATXS), Biomea Fusion Inc. (NASDAQ:BMEA), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Merck & Company, Inc. (NYSE:MRK), Abivax (OTCMKTS:AAVXF), EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), GeoVax Labs, Inc. (NASDAQ:GOVX), Organovo Holdings, Inc. (NASDAQ:ONVO), Telesis Bio Inc. (NASDAQ:TBIO), Codex DNA, Inc. (NASDAQ:DNAY), TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
Companies covered: Medtronic, Inc. (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Abbott Laboratories (NYSE:ABT), Masimo Corporation (NASDAQ:MASI), Inspire Medical Systems (NYSE:INSP), Cytek Biosciences Inc. (NASDAQ:CTKB), Rani Therapeutics Holdings Inc. (NASDAQ:RANI), Stereotaxis, Inc. (NASDAQ:STXS), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Invacare Corporation (NYSE:IVC), Aclarion Inc. (NASDAQ:ACON), PAVmed Inc. (NASDAQ:PAVM)
Companies covered: GBS Inc. (NASDAQ:GBS), BriaCell Therapeutics Corp. (NASDAQ:BCTX), BioLineRx Ltd. (NASDAQ:BLRX), Achieve Life Sciences (NASDAQ:ACHV), Pfizer, Inc. (NYSE:PFE), GlaxoSmithKline PLC (NYSE:GSK), Dr. Reddy's Laboratories Ltd (NYSE:RDY), Alpha Cognition Inc. (OTCMKTS:ACOGF), Epizyme, Inc. (NASDAQ:EPZM), Turning Point Therapeutics Inc. (NASDAQ:TPTX), Ipsen ADR (OTCMKTS:IPSEY), Bristol-Myers Squibb Company (NYSE:BMY), Argenx SE (ADR) (NASDAQ:ARGX), IVERIC bio Inc. (NASDAQ:ISEE), Blueprint Medicines Corp. (NASDAQ:BPMC), Intellia Therapeutics Inc. (NASDAQ:NTLA), Verve Therapeutics Inc. (NASDAQ:VERV), Beam Therapeutics Inc. (NASDAQ:BEAM), 2Seventy Bio Inc. (NASDAQ:TSVT), Cogent Biosciences Inc. (NASDAQ:COGT), Gilead Sciences, Inc. (NASDAQ:GILD), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Gain Therapeutics Inc. (NASDAQ:GANX), Astria Therapeutics Inc. (NASDAQ:ATXS), Viracta Therapeutics Inc. (NASDAQ:VIRX), Oncternal Therapeutics, Inc. (NASDAQ:ONCT), United Therapeutics Corporation (NASDAQ:UTHR), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Arcellx Inc. (NASDAQ:ACLX), F-Star Therapeutics Inc. (NASDAQ:FSTX), Seagen Inc. (NASDAQ:SGEN), Merck & Company, Inc. (NYSE:MRK), CRISPR Therapeutics AG (NASDAQ:CRSP), Global Blood Therapeutics (NASDAQ:GBT), Krystal Biotech (NASDAQ:KRYS), bluebird bio, Inc. (NASDAQ:BLUE), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Equillium Inc. (NASDAQ:EQ), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), Adial Pharmaceuticals Inc. (NASDAQ:ADIL), Veru Inc. (NASDAQ:VERU), NLS Pharmaceutics AG (NASDAQ:NLSP), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Atreca Inc. (NASDAQ:BCEL), Dare Bioscience (NASDAQ:DARE), Organon & Co. (NYSE:OGN), Gamida Cell Ltd. (NASDAQ:GMDA), Inhibikase Therapeutics, Inc. (NASDAQ:IKT), Geron Corporation (NASDAQ:GERN)
Companies covered: Medtronic, Inc. (NYSE:MDT), Baxter International Inc. (NYSE:BAX), Becton, Dickinson and Company (NYSE:BDX), Stryker Corporation (NYSE:SYK), Avantor Inc. (NYSE:AVTR), Edwards Lifesciences Corporation (NYSE:EW), Intuitive Surgical, Inc. (NASDAQ:ISRG), Illumina, Inc. (NASDAQ:ILMN), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Aethlon Medical Inc. (NASDAQ:AEMD), Biolase, Inc. (NASDAQ:BIOL), Bio-Techne Corp (NASDAQ:TECH), electroCore, Inc. (NASDAQ:ECOR), Implantica AG (STO:IMP-A-SDB), ReShape Lifesciences Inc. (NASDAQ:RSLS), SeaSpine Holdings Corp. (NASDAQ:SPNE), Sensus Healthcare (NASDAQ:SRTS)
